87748
3,3′,5,5′-四甲基联苯胺
TMB substrate, chromogenic, ≥98.0% (NT), powder
别名:
BM蓝, Sure Blue TMB, TMB, TMB印迹Plus, TMB底物
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
线性分子式:
[-C6H2(CH3)2-4-NH2]2
化学文摘社编号:
分子量:
240.34
NACRES:
NA.83
PubChem Substance ID:
UNSPSC Code:
12352204
EC Number:
259-364-6
MDL number:
Beilstein/REAXYS Number:
2808541
产品名称
3,3′,5,5′-四甲基联苯胺, ≥98.0% (NT)
Quality Level
assay
≥98.0% (NT)
form
powder
technique(s)
UV/Vis spectroscopy: suitable
mp
166-171 °C, 168-171 °C (lit.)
storage temp.
2-8°C
SMILES string
Cc1cc(cc(C)c1N)-c2cc(C)c(N)c(C)c2
InChI
1S/C16H20N2/c1-9-5-13(6-10(2)15(9)17)14-7-11(3)16(18)12(4)8-14/h5-8H,17-18H2,1-4H3
InChI key
UAIUNKRWKOVEES-UHFFFAOYSA-N
Application
3,3′,5,5′-四甲基联苯胺（TMB）是一种二氨基联苯胺的非致癌性取代物（Ames测试阴性）适合在ELISA实验中作为过氧化物酶底物。底物产生可溶性终产物，淡蓝色，分光光度检测在370或620-650nm可以读峰值。TMB反应能被2M H2SO4终止（产生黄色），在450nm处可读。一种高敏感，特异性试剂用于检测血液，血红蛋白实验，过氧化物酶实验。
3,3′,5,5′-四甲基联苯胺已用作以下应用的过氧物酶底物：
- 酶免疫测定(EIA)
- 间接竞争法酶联免疫吸附测定(ELISA)
- 三明治法酶联免疫吸附测定
Still not finding the right product?
Explore all of our products under 3,3′,5,5′-四甲基联苯胺
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Chronic 4 - Carc. 2
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
Sex, androgens, and whole-organism performance in an Australian lizard
Noble DWAA, et al.
Biological journal of the Linnean Society, 111(4), 834-849 (2014)
Sally L Sherwen et al.
Zoo biology, 34(4), 287-295 (2015-06-04)
Free range exhibits are becoming increasingly popular in zoos as a means to enhance interaction between visitors and animals. However very little research exists on the impacts of visitors on animal behaviour and stress in free range exhibits. We investigated
Simon Z He et al.
Leukemia & lymphoma, 56(5), 1406-1415 (2014-09-25)
Acute myeloid leukemia (AML) blasts express high levels of interlekin-3 (IL-3) receptor-α (CD123). CSL360 is a recombinant, chimeric immunoglobulin G1 (IgG1), anti-CD123 monoclonal antibody (MoAb) that neutralizes IL-3 and demonstrates anti-leukemic activity in vitro. This phase 1 study assessed safety